Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 411,320
  • Shares Outstanding, K 104,396
  • Annual Sales, $ 41,290 K
  • Annual Income, $ -37,920 K
  • 60-Month Beta 1.34
  • Price/Sales 10.09
  • Price/Cash Flow N/A
  • Price/Book 1.79
Trade MXCT with:

Options Overview Details

View History
  • Implied Volatility 56.22% ( -133.01%)
  • Historical Volatility 37.57%
  • IV Percentile 22%
  • IV Rank 10.97%
  • IV High 467.20% on 04/05/24
  • IV Low 5.58% on 11/30/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 282
  • Open Int (30-Day) 279

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.15
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.82 +3.14%
on 04/16/24
4.61 -14.53%
on 03/21/24
-0.37 (-8.58%)
since 03/15/24
3-Month
3.82 +3.14%
on 04/16/24
5.32 -25.89%
on 01/22/24
-1.27 (-24.38%)
since 01/17/24
52-Week
2.45 +60.82%
on 10/05/23
5.55 -28.94%
on 01/12/24
-1.30 (-24.81%)
since 04/17/23

Most Recent Stories

More News
Why Shares of MaxCyte Are Plummeting on Thursday

The biotech company reduced full-year guidance and expects so-so third-quarter revenue.

MXCT : 3.94 (-1.25%)
Nasdaq Futures Slip as Bond Yields Rebound, U.S. Jobs Report Looms

December Nasdaq 100 E-Mini futures (NQZ23) are trending down -0.10% this morning after three major U.S. benchmark indices closed higher on Wednesday as the latest batch of U.S. economic data prompted investors...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
MSFT : 411.84 (-0.66%)
AMZN : 181.28 (-1.11%)
META : 494.17 (-1.12%)
PLTR : 21.31 (-2.61%)
PSX : 157.25 (-0.40%)
MRO : 27.68 (-2.36%)
CALM : 60.36 (-2.49%)
PNDOR.C.DX : 1,079.000 (-0.09%)
MXCT : 3.94 (-1.25%)
BB : 2.76 (+1.10%)
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates

MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MXCT : 3.94 (-1.25%)
THMO : 0.6300 (-10.14%)
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

QURE : 4.67 (-0.64%)
MXCT : 3.94 (-1.25%)
MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

MXCT : 3.94 (-1.25%)
MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade

MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MXCT : 3.94 (-1.25%)
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MXCT : 3.94 (-1.25%)
CDMO : 6.71 (-7.45%)
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 5.24 (+29.38%)
MXCT : 3.94 (-1.25%)
MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?

MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

MXCT : 3.94 (-1.25%)
AVEO : 15.00 (unch)
MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript

MXCT earnings call for the period ending June 30, 2022.

MXCT : 3.94 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

3rd Resistance Point 4.14
2nd Resistance Point 4.07
1st Resistance Point 4.01
Last Price 3.94
1st Support Level 3.87
2nd Support Level 3.80
3rd Support Level 3.74

See More

52-Week High 5.55
Fibonacci 61.8% 4.36
Fibonacci 50% 4.00
Last Price 3.94
Fibonacci 38.2% 3.63
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar